Ameet Sarpatwari
Ameet Sarpatwari
Assistant Professor of Medicine at Harvard Medical School
Dirección de correo verificada de - Página principal
Citado por
Citado por
The high cost of prescription drugs in the United States: origins and prospects for reform
AS Kesselheim, J Avorn, A Sarpatwari
Jama 316 (8), 858-871, 2016
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review
R Stasi, A Sarpatwari, JB Segal, J Osborn, ML Evangelista, N Cooper, ...
Blood, The Journal of the American Society of Hematology 113 (6), 1231-1240, 2009
Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database
A Sarpatwari, D Bennett, JW Logie, A Shukla, KJ Beach, AC Newland, ...
haematologica 95 (7), 1167-1175, 2010
Practical, legal, and ethical issues in expanded access to investigational drugs
JJ Darrow, A Sarpatwari, J Avorn, AS Kesselheim
New England Journal of Medicine 372 (3), 279-286, 2015
Autologous 111In‐labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United …
A Sarpatwari, D Provan, S Erqou, R Sobnack, FW David Tai, AC Newland
British journal of haematology 151 (5), 477-487, 2010
Progress and hurdles for follow-on biologics
A Sarpatwari, J Avorn, AS Kesselheim
New England Journal of Medicine 372 (25), 2380-2382, 2015
The opioid epidemic: fixing a broken pharmaceutical market
A Sarpatwari, MS Sinha, AS Kesselheim
Harv. L. & Pol'y Rev. 11, 463, 2017
Expressing findings from meta‐analyses of continuous outcomes in terms of risks
J Anzures‐Cabrera, A Sarpatwari, JPT Higgins
Statistics in medicine 30 (25), 2967-2985, 2011
State initiatives to control medication costs—can transparency legislation help?
A Sarpatwari, J Avorn, AS Kesselheim
New England Journal of Medicine 374 (24), 2301-2304, 2016
Strategies that delay market entry of generic drugs
KN Vokinger, AS Kesselheim, J Avorn, A Sarpatwari
JAMA Internal Medicine 177 (11), 1665-1669, 2017
Value-based pricing and state reform of prescription drug costs
TJ Hwang, AS Kesselheim, A Sarpatwari
Jama 318 (7), 609-610, 2017
The US biosimilar market: stunted growth and possible reforms
A Sarpatwari, R Barenie, G Curfman, JJ Darrow, AS Kesselheim
Clinical Pharmacology & Therapeutics 105 (1), 92-100, 2019
Health‐related lifestyle in adults and children with primary immune thrombocytopenia (ITP)
A Sarpatwari, S Watson, S Erqou, H Anderson, J Grainger, JPT Higgins, ...
British journal of haematology 151 (2), 189-191, 2010
Experience with the priority review voucher program for drug development
AS Kesselheim, LR Maggs, A Sarpatwari
Jama 314 (16), 1687-1688, 2015
Crowdsourcing clinical trials
JJ Darrow
Minn. L. Rev. 98, 805, 2013
Perspective: Using a Drug-Safety Tool to Prevent Competition
JD Ameet Sarpatwari, J Avorn, AS Kesselheim
The New England journal of medicine, 2014
Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian …
A Sarpatwari, JB Bussel, M Ahmed, S Erqou, JW Semple, AC Newland, ...
Hematology 16 (4), 243-248, 2011
Paying physicians to prescribe generic drugs and follow-on biologics in the United States
A Sarpatwari, NK Choudhry, J Avorn, AS Kesselheim
PLoS Med 12 (3), e1001802, 2015
Promoting patient interests in implementing the federal Right to Try Act
HF Lynch, PJ Zettler, A Sarpatwari
Jama 320 (9), 869-870, 2018
Evaluating the impact of the Orphan Drug Act’s seven-year market exclusivity period
A Sarpatwari, RF Beall, A Abdurrob, M He, AS Kesselheim
Health Affairs 37 (5), 732-737, 2018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20